KZKaren B. Zur

Karen B. Zur

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Karen B. Zur has a total of 259 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Recurrent Laryngeal Nerve Reinnervation

    by Theodore A. Gobillot, Karen B. Zur

  • Open Access

    Tonsillar expression quantitative trait loci verify and expand genetic contributors to childhood atopic diseases

    by Kim Lorenz, Samuel Yoon, Carole Le Coz, Karen Zur, Andrew Wells, Neil Romberg, Benjamin F. Voight

    The spectrum of causal variants, mechanisms, and immunologic gene networks that influence pediatric atopic traits are not completely understood. Human genetic variation associated with transcript abundance (eQTLs) can help to advance our understanding, yet prior work has focused on profiling immune cell populations collected from peripheral blood primarily in adult populations, leaving uncharacterized tissue-resident lymphocytes collected from children. Here, we paired genotyping with gene expression profiling across four populations of tonsil-derived immune cell types – including previously uncharacterized germinal center B cells – collected from 103 children across development (ages 1-18). Using these data, we report cell-type specific gene networks and identify 13,393 eGenes (1,793 eGenes not previously reported in similar datasets) influenced by 27,603 eQTLs (5,199 not previously reported). We link discovered eQTLs to associations identified in pediatric and adult asthma and atopy traits, nominating 78 eGenes like TRAF3 , ZBTB10 and JAZF1 in disease relevant cell types. Our resource is freely available and exemplifies the importance of discovery in native tissues and across human development.

  • Dysphonic Children: Performers vs. Non-Performers

    by Linda Carroll, Paula Barson, Abigail Rosenberg, Karen B. Zur


  • Open Access

    Controlled decorin delivery from injectable microgels promotes scarless vocal fold repair

    by Ryan M. Friedman, Elizabeth A. Brown, Hannah M. Bonelli, Yashna Gupta, Matthew R. Aronson, Kendra McDaid, Hannah M. Oh, Eiman Abu Bandora, Karen B. Zur, Riccardo Gottardi

    Vocal fold (VF) scarring is a leading cause of poor voice, yet no therapies exist to prevent its progression. Current treatments, such as intracordal steroid injections, offer limited efficacy and carry significant off-target toxicities. To identify targeted anti-scarring strategies, we performed transcriptomics of human VF myofibroblasts, the cellular drivers of VF scarring, and identified the proteoglycan decorin (DCN) as downregulated in activated myofibroblasts. We also show a time-dependent decrease in DCN during fibrotic wound healing in a preclinical rat model of VF scarring. Administration of DCN suppressed VF myofibroblast activation by reducing pro-fibrotic gene expression, α-smooth muscle actin (α-SMA) levels, and cell contractility. DCN was encapsulated in hyaluronic acid microgels for sustained protein release for 3–4 weeks. In a rat model of VF scarring, DCN-loaded microgels prevented hallmark features of scarring, including collagen deposition and myofibroblast activation. These findings highlight DCN as a promising therapeutic and provide a sustained delivery platform with translational potential against VF scarring. Teaser Controlled decorin drug delivery from hyaluronic acid microgels attenuates myofibroblast activation to prevent vocal fold scarring, offering a translational strategy to improve post-injury voice outcomes.


  • Inhibition of the MRTF-A/SRF signaling axis alleviates vocal fold scarring

    by Ryan M. Friedman, Huy D. Truong, Matthew R. Aronson, Elizabeth A. Brown, Marco Angelozzi, Jeffrey F. Chen, Karen B. Zur, Véronique Lefebvre, Riccardo Gottardi


  • List of Contributors

    by Adam C. Adler, Aditee P. Ambardekar, Naomi Balamuth, Alexandra Berman, Tarun Bhalla, Donald L. Boyer, Andrew J. Costandi, C. Hunter Daigle, Gregory Dodson, Jeffrey M. Feldman, et al.

  • Open Access

    Systemic Use of Bevacizumab for Recurrent Respiratory Papillomatosis: Who, What, Where, When, and Why?

    by Craig S. Derkay, Emily E. Wikner, Seth Pransky, Simon R. Best, Karen Zur, Douglas R. Sidell, Adam Klein, Clark Rosen, Frederick G. Dikkers, Romaine Johnson


  • Systemic Bevacizumab Treatment for Recurrent Respiratory Papillomatosis: Long‐Term Follow‐Up

    by Ryan Ruiz, Naomi Balamuth, Luv R. Javia, Karen B. Zur

    Objectives/Hypothesis Systemic bevacizumab is a new adjuvant therapy for recurrent respiratory papillomatosis (RRP) that has shown promising preliminary results in children. The objective of this study was to report the largest series to date that includes long-term follow-up data on bevacizumab treatment. Study Design Retrospective chart review. Methods Retrospective review of seven pediatric patients treated within the past 6 years with systemic bevacizumab for RRP refractory to traditional debridement. Results All seven patients had a significant reduction in disease burden after initiation of systemic bevacizumab. There have been no major complications associated with systemic therapy so far. Median duration of bevacizumab treatment was 2.13 years. Three of the seven patients have been on treatment for over 3 years with the longest duration of treatment in our first patient now at 5.5 years. One patient experienced significant disease recurrence on two occasions when therapy was temporarily discontinued and was recently diagnosed with squamous cell carcinoma of the lung. Conclusion Systemic bevacizumab is an effective therapy for cases of severe RRP with promising results both in short-term and long-term follow-up. Side effects are minimal. Patients must be followed closely to determine appropriate dosing intervals to control disease and to screen for disease progression. Level of Evidence IV Laryngoscope, 2022


  • Intubation‐Related Laryngeal Deficiency and Vocal Fold Immobility in Pediatric Premature Patients

    by Karen B. Zur, Jennifer Douglas, Linda M. Carroll

    Objectives/Hypothesis: We report a posterior laryngeal rating system and measures of voice disability in pediatric patients undergoing phonosurgery for vocal fold paralysis. Posterior glottic deficiency may account for persistent voice disability.Study Design: Retrospective Study.Methods: Retrospective analyses of 66 subjects with primary unilateral vocal fold paralysis were reviewed for the status of posterior glottis and voice disability (Pediatric Voice Handicap Index [pVHI]). Gestation age (GA), weight, and medical/surgical history were reviewed. The width, length, and depth of the larynx were analyzed to create a reproducible rating scale.Results: Mean GA was 29 weeks, with an intubation history for all subjects, with 90% having a left vocal fold immobility. Cardiac surgery was performed in 92% of subjects. A progressive rating (type 0–3) Benjamin Defect Severity Scale (BDSS) was developed to rate the absence or presence of a posterior abnormality. BDSS‐2 and BDSS‐3 subjects were more likely to have low birth weight. Extremely preterm GA was more likely to be associated with BDSS‐1 (mild) or BDSS‐2. History of multiple and prolonged intubations were seen more frequently in BDSS‐2 or BDSS‐3. Post‐op pVHI reduced an average of 15 points for BDSS‐0 to BDSS‐2, but only 3 points for BDSS‐3. Post‐op pVHI matched normal values for preintervention dysphonic children.Conclusions: The presence of a persistent breathy voice after intervention for unilateral vocal fold immobility is potentially associated with posterior glottic defects. Low birth weight with multiple/prolonged intubation is more likely to be present with higher‐grade BDs, whereas low GA is more likely to be associated with BDSS‐1 to BDSS‐2.Level of Evidence: 4 Laryngoscope, 131:2550–2557, 2021